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ABSTRACT 
STUDY OF LIPID PROFILE IN INTRACEREBRAL HAEMORRHAGE 
BACKGROUND  
Stroke caused by intracerebral haemorrhage (ICH) has high mortality rate. 
Among various risk factors for ICH, hypertension is the most important factor. 
Certain population studies have reported a paradox of inverse association between 
serum cholesterol and risk of ICH. This study is to look for correlation between 
lipid profile and ICH. 
AIMS AND OBJECTIVES  
The study is designed to evaluate the serum lipid profile  
total cholesterol (TC), triglycerides (TGL), high density cholesterol (HDL-C),very 
low density cholesterol (VLDL-C) and low density cholesterol (LDL-C) in 
intracerebral haemorrhage patients and look for correlation. 
 METHODOLOGY 
 50 patients with ICH admitted in Thanjavur Medical College Hospital, 
Thanjavur who fulfilled the inclusion and exclusion criteria were selected. It is a 
hospital based observational study. History, clinical examination and investigations 
(CT & MRI Brain and basic blood biochemistry with serum lipid profile) were 
collected and the data were analysed statistically.  
RESULTS 
Majority of the ICH patients in our study were > 55 years and were males. 
Basal ganglia was the commonest site and hypertension was the important risk 
factor. The total serum cholesterol was < 200mg/dl in 72 % of our patients, with a 
mean of 168.09 ±43.74mg%. Serum triglyceride level was <150 mg/dl in 74%, 
with a mean of 124.12 ±50.76mg%. LDL-cholesterol was <130mg /dl in 68 % of 
patients, with mean of 108.26±43.31mg%. HDL-C was < 40 mg/dl in 76% of 
patients and VLDL-C was < 30mg/dl in 72% patients. The various lipid fractions 
observed were found to be low in majority of our ICH patients (p value < 0.05), 
suggesting a negative association between the two. The results obtained were 
comparable to other similar studies. 
CONCLUSION 
Majority of intracerebral haemorrhage patients in our study had lower levels 
of total cholesterol, triglyceride, HDL-C, LDL-C and VLDL-C. Whether the 
inverse association between serum lipid levels and ICH is a true causal association 
or only by chance due to other common confounding factors needs to be evaluated 
with large scale studies. 
Key words: Intracerebral haemorrhage, lipid profile, serum cholesterol, 
triglyceride, HDL-C, LDL-C, VLDL-C. 
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INTRODUCTION 
Stroke is a neurological emergency. Stroke means being suddenly 
struck. It is also sometimes referred to as brain attack1. Stroke is one of the 
most important non communicable diseases causing death. Stroke or 
Cerebro Vascular Accident (CVA) is “abrupt onset of a neurologic deficit 
that is attributable to a focal vascular cause” 2. World Health Organization 
defines stroke as “rapidly developing clinical signs of focal (or global) 
disturbance of cerebral function, with symptoms lasting 24 hours or longer 
or leading to death, with no apparent cause other than of vascular origin”. 
 The two major categories of stroke are ischemic stroke and 
haemorrhagic stroke. Intracerebral haemorrhage attributes to 10.7 % of 
stroke from all causes3. It is diagnosed by a CT scan of brain which is the 
most important tool in evaluation of a patient with stroke. Intracerebral 
haemorrhage (ICH) is a grave disease inspite of growing knowledge in 
medicine. The outcome of patients is based on the severity of bleeding4. 
Symptoms are produced by the blood which causes mass effect disrupting 
the neural tissues, from the direct toxic nature of blood or due to increase in 
intracranial tension5,6. The fatality rate of ICH is high. There are limited 
treatment options available. Hence prevention of ICH is the most prudent 
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way to limit the disease burden. This warrants thorough knowledge about 
various risk factors that predispose to ICH. 
Hypertension is the most important and well established risk factor 
for ICH7,8. Other risk factors are race, alcoholism, smoking, coagulopathy, 
thrombocytopenia9 etc. Certain studies have reported a paradox of increased 
ICH incidence among people with low serum cholesterol. This study is to 
see the various derangements in the lipid profile of patients with ICH and 
look for correlation. 
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AIMS AND OBJECTIVES OF THE STUDY 
1. The study is designed to evaluate the serum lipid profile –  
a. Total Cholesterol (TC),  
b. Triglycerides (TGL), 
c. High Density Cholesterol (HDL-C), 
d. Very Low Density Cholesterol (VLDL-C) and 
e. Low Density Cholesterol (LDL-C) in intracerebral 
haemorrhage (ICH) patients.  
 
2.  To assess for correlation between lipid profile levels and              
intracerebral  haemorrhage (ICH). 
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REVIEW OF LITERATURE 
HISTORICAL ASPECTS 10, 11 
Stroke was initially called as apoplexy during the period of 
Hippocrates. It was in the early 16th century the word stroke came into use 
in the English literature. It was Galen who thought that it was due to 
interruption of flow of some “Vital Spirit” to brain which was later on found 
to be blood. Slowly the term apoplexy disappeared and was replaced by 
cerebrovascular diseases. 
It was Osler who mentioned about massaging the affected limbs to 
prevent contractures. In 1946, Kubik and Adams gave  clinicopathological 
analysis of occlusion of the basilar artery. Miller Fisher in 1951 gave the 
clinical profile of patients who had internal carotid artery (ICA) occlusions 
in the neck. 
Later on different diagnostic and therapeutic changes came into 
limelight. It was way up in 1950 Lawrence Craven described the effect of 
aspirin on clotting of blood. In 1960s the idea of use of aspirin in preventing 
clotting disorders emerged. Major risk factors for stroke were stratified in 
1960s and this caused fall in mortality. With advent of CT scans in early 
1970s clear distinction could be made between ischemic and haemorrhagic 
strokes12. 
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In 1990s tissue plasminogen activator (t-PA) was approved by FDA 
for ischemic strokes. At present the treatment of stroke is brought about by 
stroke unit which provides comprehensive assessment of various risk factors 
and holistic treatment. 
EPIDEMIOLOGY 
 Stroke or Cerebro Vascular Accident (CVA) is sudden onset of focal 
neurologic deficit, caused by vascular lesion. Stroke has emerged as one of 
the most important causes of death among non communicable diseases.  
Mortality from stroke is high especially in Asia. It is also the major cause of 
disability in adults. 30% of stroke survivors need assistance for day care 
activities, 20% of survivors need help for walking and 16% of survivors 
need hospital care. 
 India bears the double burden of both non communicable and 
communicable diseases. Of the non communicable diseases stroke 
contributes to majority of cases. Rate of incidence of stroke in many 
population based studies in India is estimated to be 119-145/1,00,000 13.  
Gone are the days when stroke was considered to be a disease of affluent 
people. In recent times, the incidence of stroke is increasing among people 
in rural areas and people of lower socioeconomic status, thereby increasing 
the burden of the disease.  
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Broadly stroke is classified14 as  
1. Ischemic stroke (80%) 
2. Haemorrhagic stroke (20%)  
Haemorrhagic stroke includes  
Intracerebral  Haemorrhage (ICH) and  
Subarachnoid Haemorrhage (SAH) 
10% of all strokes are due to ICH. The significance of ICH comes from the 
fact that 30 day fatality rate is as high as 50%. 
Ischemic stroke14 
Common etiologies of ischemic stroke are large vessel thrombosis, 
lacunar stroke, artery to artery embolus especially from carotids, 
cardioembolic causes like atrial fibrillation, myocardial infarction, valvular 
lesions and endocarditis. 
Uncommon etiologies include hypercoagulable states, vasculitis, 
fibromuscular dysplasia and moyamoya disease. 
INTRACEREBRAL OR INTRAPARENCHYMAL HAEMORRHAGE  
HYPERTENSION 
The single most important cause for ICH is hypertension7, 8.  
NON HYPERTENSIVE CAUSES 7 
 Vascular malformations like 
• arteriovenous malformations (AVM),    
• saccular aneurysms, 
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• cavernous angiomas 
 Cerebral Amyloid Angiopathy (CAA) 
 Tumors 
 Bleeding disorders 
 Use of anticoagulants  
 Use of  fibrinolytic agents 
 Vasculitis 
 Sympathomimetic agents (including amphetamine and cocaine) 
 Haemorrhagic infarction 
 Trauma 
 Hemoperfusion Syndrome 
PATHOGENESIS OF ICH 5, 15 
Presence of long standing systemic hypertension leads to fibrinoid 
necrosis of the penetrating and sub cortical arteries, thereby causing their 
walls to become weak. This leads to tiny outpouchings called Charcot-
Bouchard micro-aneurysms, the main factor predisposing to ICH. 
The main sources of bleeding are from the deep penetrating arteries of 
the circle of Willis, including the lenticulostriate, thalamogeniculate, 
thalamoperforating arteries and basilar artery perforators. Any abrupt raise 
in blood pressure also precipitates ICH. Rupture of vascular malformation is 
the next common cause for ICH. 
If the blood volume is large it distorts the neural structures and raises 
intracranial tension causing
and death. 
FIGURE.1. INTRACEREBRAL HAEMORRHAGE
CAUSES OF INTRACEREBRAL 
HYPERTENSION: 
Systemic hypertension is the major cause for ICH.
about 72 % to 81% of ICH
putamen, cerebral lobes,
8 
 midline shift sometimes leading to herniation 
 
HAEMORRHAGE: 
 It accounts for 
16, 17
. The common sites of hypertensive ICH
 thalamus, pons, caudate and cerebellum
 
 are 
4
. 
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Hypertensive intracerebral haemorrhages are also called primary ICH and 
only around two percent of hypertensive ICH occur in multiple sites in 
brain. Primary intraventricular haemorrhage is uncommon. If it occurs it is 
probably due to bleeding from choroid plexus. Hypertension also adds to the 
risk of rupture of the arteriovenous malformations (AVM) and aneurysms. 
NON HYPERTENSIVE   CAUSES 
VASCULAR MALFORMATIONS18, 19, 20, 21 
Vascular malformations like arteriovenous malformations (AVM) or 
cavernous angiomas can cause ICH. These occur often involving the 
cerebral sub cortical white matter.  
There are certain peculiarities among this subgroup of patients 
compared to hypertensive ICH. 
 There size of haematoma with this type of ICH is smaller.  
 The onset of clinical features is slower.  
 If there is coexisting subarachnoid haemorrhage (SAH) in the 
imaging, it is a clue to etiology of vascular malformation. 
 Younger individuals are affected by this type of ICH.  
 The occurrence of such ICH is higher among females as opposed to 
hypertensive ICH. 
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AVM can occur in both brain and spinal cord. It has a tangle of blood 
vessels which has a number of feeding arteries with one large vein that 
drains it without capillaries connecting these two.  
Any abrupt increase in blood pressure or trivial trauma can cause 
haemorrhage. These are frequently lobar haemorrhages as opposed to 
hypertensive bleeds that occur in basal ganglia. 
Cavernous angiomas are frequently supratentorial involving frontal, 
temporal and parietal lobes. These are mostly asymptomatic but can cause 
ICH. The tendency to bleed is comparatively lesser with cavernous 
angiomas as opposed to AVM. They rarely present as progressive deficits 
due to recurrent and small bleeds. In MRI Brain, cavernous angiomas are 
seen as irregular lesions with mixed T2 signal in centre and low intensity 
signal surrounding it. Saccular aneurysms that are usually associated with 
SAH can also cause ICH. Charcot Bouchard aneurysms are small 
outpouchings of perforating arteries which represent a degenerative process 
as a result of chronic hypertension and are hypothesized to be associated 
with ICH22, 23. 
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FIGURE 2.ARTERIOVENOUS MALFORMATION 
CEREBRAL AMYLOID ANGIOPATHY (CAA) 
Deposition of Congo red positive amyloid in the cerebral blood 
vessels most often the small and medium sized ones are characteristic 
feature of cerebral amyloid angiopathy24.There is breakdown of the blood 
vessel wall. The amyloid that is associated with CAA is Aβ type. This 
process mainly affects the blood vessels of cerebral cortex and the 
leptomeninges. The process affects patchy areas of brain alternating with 
normal areas. Severe cases will have development of micro aneurysms, 
vessel wall splitting, vessel wall inflammation or fibrinoid necrosis. 
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 The incidence of CAA rises with increasing age25. Almost 60% of 
autopsies in elderly over 90 years of age have revealed this pathological 
change26. The presence of amyloid weakens the vessel wall and leads to 
rupture of the blood vessel. CAA causing ICH is rare among younger 
individuals less than 55 years of age.  
ICH associated with CAA is frequently lobar owing to the fact that 
the affected vessels are superficially located. The disease process affects 
blood vessels widespread in the brain so they are common causes of 
multiple and recurrent ICH in older population. Similar pathological process 
occurs in individuals with Alzheimer’s disease27. CAA is associated with 
certain cases of dementia, seizures or TIA. 
 
 
FIGURE 3. AMYLOID ANGIOPATHY SHOWING AMYLOID 
DEPOSITS IN THE VESSEL WALL 
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TUMORS 
The occurrence of ICH as a result of brain tumor bleed accounts only 
for a rare subset of patients around 10% of ICH 28,29. This can occur both 
with primary or metastatic malignancies. The most common tumors 
associated with ICH are metastatic malignant melanoma, choriocarcinoma, 
renal cell carcinoma, primary brain tumors like glioblastoma multiforme 
and oligodendroglioma28,30,31 . The propensity of the tumor to bleed depends 
upon the vascularity of the tumor and the malignant nature of the tumor. 
There is additional component of vessel wall invasion for metastatic 
choriocarcinoma. ICH may be the first manifestation of the tumor in certain 
cases. 
Imaging and clinical features suggestive of tumor bleed33, 34 are  
 Papilledema during  presentation. 
 Unusual site of occurrence of bleed as compared to 
hypertensive ICH.  
 Multiple haemorrhages. 
 Haematoma being spherical. 
 Non contrast CT Brain shows a low density central area due to 
necrosis surrounded by high density ring. 
 Gross cerebral edema out of proportion to the amount of bleed.  
 Presence of contrast enhancing lesion in the surrounding. 
Tumor bleeds carry grave prognosis with high mortality rate. 
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BLEEDING DISORDERS   
Coagulation disorders are rare causes of ICH. Hemophilia causes ICH 
in 2.5-6 % of affected patients. ICH is an important complication of acute 
leukemias particularly ALL. Thrombocytopenia especially when platelet 
count falls less than 10,000 causes ICH. 
USE OF ANTICOAGULANTS 
Use of anticoagulants has been associated with increased incidence of 
ICH about 8 to 11 times that of normal population. About 10% of cases of 
ICH are due to use of anticoagulants34,35.Greater the degree of 
anticoagulation, higher is the risk particularly when the International 
Normalised Ratio (INR) >4 37,38. This type of ICH has peculiar feature that it 
occurs over a protracted period. Cerebellar and lobar ICH have this type of 
ICH as a common cause next to hypertension. The mortality rate is higher 
with this type and there is also greater tendency for the haematoma volume 
to expand. Leukoaraiosis when present in large areas has a greater risk of 
bleed with concomitant anticoagulant use. 
FIBRINOLYTICS 
ICH is a serious complication with use of fibrinolytics like 
streptokinase and tissue-type plasminogen activator (t-PA). This 
complication frequently follows shortly after thrombolysis. Usually the site 
of bleed in such cases is lobar. ICH occurs as a complication of use of 
recombinant t-PA (rt-PA) used for intravenous thrombolysis for acute 
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ischemic stroke. The incidence of ICH in intravenous thrombolysis for acute 
ischemic stroke is about 6.4%. Intra arterial thrombolysis also causes ICH in 
about 11% of cases38,39. 
 Risk factors for this complication are large stroke with major 
neurological deficit during treatment, mass effect and edema in CT Brain, 
presence of hyperglycemia and longer duration between onset of stroke and 
initiation of thrombolytic therapy40. 
VASCULITIS 
Cerebral vasculitic disorders usually cause ischemic stroke. The rare 
cause of ICH among the vasculitic disorders is Granulomatous angiitis of 
the CNS otherwise called as isolated angiitis of CNS41. 
 
FIGURE.4 BEADING OF VESSELS IN ANGIOGRAPH OF ISOLATED 
ANGIITIS OF CNS 
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       Isolated angiitis of CNS occurs without any features of systemic disease 
like fever, weight loss or elevated erythrocyte sedimentation rate (ESR)42. 
There is infiltration of mononuclear cells in the walls of cerebral arteries 
and veins. It may also be accompanied by micro aneurysms. The site of 
bleed is usually lobar. The CSF shows lymphocytic pleocytosis with 
increase in protein. Angiography reveals beading of the affected blood 
vessels. 
 Polyarteritis nodosa may also cause ICH and it is usually associated 
with systemic features of vasculitis. 
SYMPATHOMIMETIC DRUGS 
           The most common culprit drugs are amphetamine, methamphetamine 
and pseudoephedrine. All routes including intravenous, intranasal and oral 
abuse have been implicated. ICH occurs within minutes to hours after the 
drug has been taken. The site of bleed is usually sub cortical white matter. 
The main mechanisms predisposing to ICH are due to transient increase in 
blood pressure and also due to spasm of blood vessels in response to the 
drug44. Sometimes there is associated beading of the blood vessels but it is 
reversible with treatment of steroids. 
Phenylpropanolamine, a nasal decongestant and anorexigenic drug is 
also implicated as a cause of ICH. Cocaine causes both ICH and SAH. ICH 
is usually in the sub cortical white matter. It is mainly due to drug induced 
vasoconstriction and vasculitis. 
17 
 
HAEMORRHAGIC INFARCTION 
Haemorrhagic transformation of the infarction is a dreadful 
complication. Scattered petechial haemorrhages are seen in the necrotic 
tissue. Main risk factors are large infarcted tissue, embolic stroke and 
cerebral venous sinus thrombosis. It occurs due to reperfusion of the 
damaged blood vessels in the necrotic area. 
The distinguishing features of haemorrhagic infarction from that of 
primary ICH are  
 Usually associated with an embolic source.  
 Features of raised ICT are absent. 
  CT Brain shows spotted areas of hyperdensity without midline shift. 
 Usually cortical in location. 
 Ventricular bleed is uncommon. 
 Branch occlusion in angiography.  
HEAD TRAUMA 
Intracranial haemorrhages may be caused by cerebral contusion 
injury. It is classified under traumatic bleed. Usually they are multiple and 
occur in basal frontal, anterior temporal and occipital areas. 
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HEMOPERFUSION SYNDROME 
This is a rare cause of ICH occurring in about 1% of cases after 
carotid endarterectomy especially in the initial postoperative period. It 
occurs mostly in those patients where there is hemodynamically 
compromised cerebral circulation prior to the procedure. It may also occur 
after carotid stenting. 
RISK FACTORS FOR ICH9 
AGE  
Increasing age is an important factor predisposing to ICH. 
RACE  
Certain groups of population have an increased risk of developing 
ICH like the Africans, Asians and Hispanics. 
SYSTEMIC HYPERTENSION 
Systemic hypertension is the most important and most well studied 
risk factor for ICH.  
ALCOHOL45,46 
Consumption of alcohol especially in large amounts [more than 21 
units per week] is a risk factor. 
SMOKING47 
Smoking is associated with risk of ICH, especially in those who 
smoke more than 20 cigarettes a day. 
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LOW CHOLESTEROL48,49 
There are many population based studies that have revealed that low 
serum cholesterol levels [especially when less than 160mg %] are associated 
with sizable increase in the occurrence of ICH. 
GENETIC FACTORS50 
Presence of certain alleles of apoE ∈2 and ∈4 are associated with 
more risk of ICH due to cerebral amyloid angiopathy. 
CLINICAL FEATURES51,52 
In the pre CT scan era the distinction between a haemorrhagic stroke 
and ischemic stroke was mainly relied upon on the mode of onset and the 
characteristic clinical features. Depending on the amount of blood and the 
site of bleed there are different clinical presentations.  
ICH usually occurs while the patient is awake and during activity in 
contrast to ischemic stroke where the patient wakes up with neurological 
deficit. The features of increased intracranial tension like headache53, 
vomiting and altered consciousness are present. Altered sensorium is 
present in about 60% of patients with more than half worsening to the level 
of coma. Coma occurs mainly in those with intraventricular extension. The 
presence of coma in a case of ICH also signifies that it is massive and is 
usually associated with grave prognosis. Patients with SAH may also have 
additional features of neck stiffness and features of meningism. 
20 
 
The neurological deficit in ICH often shows progression over period 
of hours relating to progressive increase in the haematoma volume. The 
amount of neurological deficit also depends upon the site of haemorrhage. 
Seizures occur only in a small subset of patients especially more common in 
those with lobar haemorrhage. 
Hypertension is common at the time of presentation. Patient also will 
have other features of hypertension like left ventricular hypertrophy, 
hypertensive retinopathy and nephropathy. Unlike non hypertensive causes 
of ICH that tend to evolve slowly, hypertensive ICH usually evolves within 
short period of around  30–90 minutes. 
The various topographical locations of ICH present with different 
neurological findings4. The site of ICH also depends upon various etiologies 
and therefore can be a clue towards etiological diagnosis. Hypertensive 
haemorrhages most commonly involve basal ganglia. Lobar haemorrhages 
can be due to hypertension in 50% of cases but can also be associated with 
many non hypertensive   causes. 
21 
 
 
 
1. cerebral lobes;2.basal ganglia; 3.thalamus; 4.pons; 5.cerebellum 
 
FIGURE.5.COMMON SITES OF ICH 
 
 PUTAMINAL HAEMORRHAGE 
Putamen is the most common site of ICH, accounting for about 35% 
of ICH. It is commonly associated with internal capsule involvement. It is 
classically associated with contralateral motor weakness, sensory 
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disturbance, aphasia and sometimes visual disturbances. Homonymous 
hemianopia and horizontal gaze palsy can occur. 
If the bleed is massive, it can cause coma and uncal herniation. Uncal 
herniation causes third nerve palsy and presents with pupillary abnormality. 
The presence of third nerve dysfunction is one of the poor prognostic signs. 
The presence of intraventricular extension of the ICH is also a poor 
prognostic factor. 
 CAUDATE HAEMORRHAGE54 
It occurs in about 5% of patients of ICH. The most common etiology 
is hypertension. The source of bleed is the penetrating arteries of anterior 
and middle cerebral arteries. The onset of the disease is abrupt with 
headache and vomiting. 
There is frequent intraventricular extension leading to hydrocephalus. 
Usually there are neuropsychological abnormalities like abulia, 
disorientation and amnesia. Motor weakness is usually mild. There is no 
aphasia. Caudate haemorrhages have a benign course and good outcome. 
Patients usually recover fully without any neurological deficit.  But some 
may have persistent neuropsychological abnormalities. 
THALAMIC HAEMORRHAGE 
10 to 15% of ICH is due to thalamic haemorrhages. The most 
common cause is hypertension. Depending on the size of haematoma, it can 
enlarge medially to the third ventricle, laterally into the internal capsule, 
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superiorly into the parietal white matter and inferiorly into dorsal midbrain 
and sub thalamic nuclei. There is abrupt onset of contralateral motor deficit 
with hemi sensory loss. 
The most important oculomotor findings are vertical gaze palsy, 
miotic and unreactive pupil. These patients sometimes have Parinaud 
syndrome. Large haematoma volume and presence of hydrocephalus are 
poor prognostic signs. 
LOBAR HAEMORRHAGE 
Lobar haemorrhage is the second most common cause of ICH 
contributing to about 25% of cases. These are the sub cortical white matter 
haemorrhages. Any cerebral lobe can be affected but involves most 
commonly the parietal, temporal and occipital lobes. 
Hypertension is the cause in about 50% of cases. The peculiarity of 
lobar haemorrhages is that there are non hypertensive   causes related to 
lobar ICH like AVM, intracranial tumors, use of sympathomimetic drugs, 
bleeding disorders and in the elderly cerebral amyloid angiopathy. Lobar 
haemorrhages present with headache, seizures, sensorimotor deficits and 
aphasia. The occurrence of coma is less frequent. Death from lobar ICH is 
usually lower than that from other sites of ICH. 
CEREBELLAR HAEMORRHAGE 
5 to 10% of ICH are due to cerebellar haemorrhage. These originate 
from superior cerebellar or posterior inferior cerebellar arteries. 
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Hypertension is the common risk factor for cerebellar ICH. Few cases have 
been associated with rupture of AVM and anticoagulant use. 
The patient typically presents with sudden onset of vertigo, inability 
to stand and gaze palsy. Headache and vomiting are more common with 
cerebellar ICH. There is ipsilateral appendicular ataxia and ipsilateral gaze 
palsy. The course of cerebellar ICH is often not predictable. Features of 
increased ICT and brainstem compression are more common complications 
of cerebellar ICH. Brainstem compression is frequently the cause of 
mortality. Such patients need urgent surgical decompression, which 
improves outcome. 
PONTINE HAEMORRHAGE55 
5% of cases of ICH are due to pontine haemorrhages. Pontine 
haemorrhages occur bilaterally and are usually due to hypertension. There is 
frequent extension of this type of ICH into the fourth ventricle. Severe 
headache occurs and the patient rapidly deteriorates to coma. Quadriplegia 
with spasmodic decerebrate posturing and hyperthermia with pinpoint 
pupils occur. There is also horizontal gaze palsy with one and a half 
syndrome and ocular bobbing. 
Massive haemorrhage can lead to death within few hours. 
Hyperthermia, tachycardia, respiratory abnormalities and hydrocephalus are 
predictors of mortality. 
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MESENCEPHALIC HAEMORRHAGE 
Mesencephalic haemorrhages are rare. Usually it is an extension from 
thalamus, putamen, cerebellum or pons. Hypertension, rupture of AVM and 
blood dyscrasias are the causes. They present with ataxia, oculomotor palsy, 
vertical gaze palsy and contralateral hemiparesis. Midbrain ICH when small 
can solely present with isolated ophthalmoplegia. 
MEDULLARY HAEMORRHAGE 
Haemorrhage into medulla oblongata occurring in isolation is very 
rare. Usually it is an extension from pontine haemorrhage. Patients present 
with sudden onset of headache, dizziness, dysphagia, dysphonia, dysarthria, 
ataxia, nystagmus, Horner’s syndrome, hiccups, limb weakness or 
hypoglossal nerve palsy. Hypertension, AVM and anticoagulant usage are 
common causes of medullary haemorrhage. Mortality rate is around 20%. 
INTRAVENTRICULAR HAEMORRHAGE 
Intraventricular extension of haemorrhage from caudate, thalamus, 
putamen and cerebral lobes is an important complication. Primary 
intraventricular haemorrhage is rare. It contributes to about 3 % of cases. 
The source of bleed for primary intraventricular haemorrhage is from the 
subependymal blood vessels. Hypertension, AVM, sympathomimetic drugs, 
tumors and blood dyscrasias are the causes. The patients typically present 
with sudden onset of headache, vomiting, altered sensorium and minimal 
neurological deficit. Among the cases having AVM those with anterior 
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communicating artery aneurysm usually rupture into the lateral ventricles. 
Small AVM that are situated in the medial part of thalamus and basal 
ganglia cause primary intraventricular haemorrhage. Sometimes AVM are 
located within the ventricles. 
MRI Brain with angiography is more reliable in diagnosing the 
presence of AVM in such cases. Those patients who are alert initially 
recover with residual deficit. But those who are comatose initially have high 
degree of mortality due to brainstem compression. 
 
DIAGNOSIS OF INTRACEREBRAL HAEMORRHAGE 
CT BRAIN32,56 
Sudden onset of symptoms with altered sensorium in a patient 
presenting with high blood pressure suggests a possible diagnosis of ICH. 
The introduction of CT scan in 1973 by Hounsfield revolutionized the 
diagnosis of stroke patients, distinguishing the ischemic and haemorrhagic 
strokes. Non Contrast CT scan of the brain is the most sensitive and gold 
standard diagnostic tool to diagnose acute ICH. It is also less time 
consuming compared to MRI scanning. 
Blood appears as hyperdense lesion in non-contrast CT brain. It 
appears dense and homogenous. There is associated mass effect. It remains 
hyperdense for few weeks and later on becomes isodense with surrounding 
brain tissue. The site of bleed, size, any intraventricular extension, mass 
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effect and presence of hydrocephalus can be found by CT Brain. Late 
contrast enhancement in CT Brain may occur after 2 to 4 weeks and can 
remain so for long time in few cases. 
 
 
 
FIGURE 6. NON CONTRAST CT BRAIN SHOWING ACUTE LEFT 
BASAL GANGLIA ICH 
CT is more sensitive for supratentorial haemorrhages. As bone 
induced artifacts obscure clear viewing of posterior cranial fossa, CT scan is 
less reliable for posterior cranial fossa ICH. MRI is useful in posterior 
cranial fossa lesions.  
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Sometimes CT angiography is used in young patients to identify 
AVM. The presence of “dot sign” in post contrast CT is a sign that there is 
an active bleeding. 
MRI BRAIN 
 
TABLE.1. MRI BRAIN IN INTRACEREBRAL HAEMORRHAGE 
 
 Isointense with surrounding brain 
                     Hypointense 
                     Hyperintense  
                     Marked Hypointense   
 Marked Hyperintense 
DURATION 
AFTER 
ICH 
SOURCE OF 
RADIOLOGICAL 
SIGNAL 
T1-
WEIGHTED 
MRI 
T2-
WEIGHTED 
MRI 
Hyperacute 
(initial hours) Oxyhaemoglobin            Or   
Acute (1–3 days) Deoxyhaemoglobin           Or  
Early subacute 
(3–7 days) 
Intracellular 
methaemoglobin 
 
 
Late subacute 
(1–4 weeks) 
Extracellular 
methaemoglobin   
Chronic Haemosiderin   
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Interpretation of ICH in MRI is more complicated. There is a change 
in appearance of haemorrhage as the time advances because the red cells are 
lysed and there is degradation of hemoglobin that is engulfed by 
macrophages to form hemosiderin. Other factors like the amount of protein, 
water, fibrin and clot retraction also change the MRI appearance. Gradient 
echo (GRE) MRI or T2 susceptibility weighted MRI is important in 
diagnosis. 
But the haemorrhage can mask the underlying cause in some cases. 
So in suspected patients a repeat MRI after 3 months has to be done to find 
the presence of underlying cause. Sometimes angiographic studies are 
needed. MRI is sensitive in diagnosing small ICH.  
 
The presence of any cause for ICH can be delineated by MRI.  
 AVM are seen as clusters of blood vessels.  
 Cavernous angiomas are seen as small hyperintense lesions 
surrounded by hypointense rim. 
 Tumor bleed is seen as a central hypointense lesion due to necrosis 
surrounded by hyperintense signal. 
 Vasculitis may be suspected when there are coexisting ischemic and 
haemorrhagic lesions. 
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ANGIOGRAPHY 
In order to find a potentially treatable cause for ICH, angiographic 
studies need to be done in selected patients. Angiography is indicated in any 
young patient with ICH and certain elderly patients with lobar haemorrhage. 
 
 
 
FIGURE.7.ANGIOGRAPHIC PICTURE SHOWING 
ARTERIOVENOUS MALFORMATION 
 
The presence of aneurysms, AVM,cavernous angiomas or CNS vasculitis 
can be identified by angiography. 
In a study Zhu et al, the angiographic abnormalities were found in 
48% of cases less than 45 years of age as opposed to 0 to 10% of older 
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patients. If the initial angiography is negative, it may be repeated 2 to 4 
weeks after the haematoma resolves in those patients where secondary 
causes of ICH are strongly suspected. 
HAEMORRHAGES IN MULTIPLE SITES 
Presence of multiple haemorrhages in neuroimaging may suggest  
 Cerebral amyloid angiopathy 
 Tumor bleed 
 Bleeding disorders  
 Use of thrombolytics   
 Cerebral vasculitis. 
MANAGEMENT 
INITIAL EVALUATION  
Intracerebral haemorrhage is a medical emergency. The 
comprehensive and coordinated work of critical care physician, neurologist, 
radiologist and neurosurgeon is of utmost importance. Most of the patients 
are comatose while they arrive at the casualty. 
 The first 24 hours is the most crucial part of management. The 
American Stroke Association advises Intensive Care management 
especially during this period. 
 Airway, Breathing and Circulation should be maintained. 
 Early endotracheal intubation should be done in comatose individuals 
to protect the airways, to prevent aspiration and hypoxia. 
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 The patient’s neurological status has to be assessed hourly and 
Glasgow coma scale score should be calculated. 
 Blood pressure and other vital parameters should be constantly 
monitored. 
 Immediate non contrast CT Brain should be taken to find the cause of 
stroke. When ICH is the cause of stroke, the site and size of bleed is 
assessed to know the prognosis and plan further management. 
 Laboratory investigations including the blood sugar, urea, creatinine, 
complete haemogram with coagulation studies and lipid profile have 
to be taken.  
The prognosis and mortality of ICH patients can be assessed with 
ICH scoring system using age, haematoma volume, presence of 
intraventricular extension, infratentorial bleed and Glasgow coma scale 
score as variables. The minimal score is 0 and maximum score is 5. The 30 
day mortality rate and the ability of patients to walk independently at 1 year 
are assessed by this scoring system. 
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TABLE. 2. ICH SCORING SYSTEM 2 
 
Clinical or Imaging Variable Point 
Age  
 
<80 years 0 
>80 years 1 
Haematoma Volume  
 
<30 cc 0 
>30 cc 1 
Intraventricular Haemorrhage   
No 0 
Yes 1 
Infratentorial Origin of 
Haemorrhage   
No 0 
Yes 1 
Glasgow Coma Scale Score  
 
13–15 0 
5–12 1 
3–4 2 
Total Score Sum of each category above 
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TOTAL ICH SCORE DAY 30 MORTALITY (%) 
Walk Independently at 
1 YEAR (%) 
0 0 70 
1 13 60 
2 26 33 
3 72 3 
4 97 8 
5 100 None 
 
 
MANAGEMENT OF INCREASED BLOOD PRESSURE57 
The volume of haematoma generally increases with high blood 
pressure (BP). Most of the ICH patients have markedly increased BP during 
presentation. BP control in ICH should be done balancing for cerebral 
perfusion. 
One important clinical trial INTERACT (INTENSIVE BLOOD 
PRESSURE REDUCTION IN ACUTE CEREBRAL HAEMORRHAGE 
TRIAL) assessed the goal of BP reduction in hypertensive ICH patients. 
They had two groups one with target level of Systolic BP (SBP) 
<180mmHg and another group with target of SBP < 140mmHg using 
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intravenous (IV) antihypertensives. They observed a statistical decrease in 
the haematoma growth and edema in those whose target SBP was 
<140mmHg. It is prudent to maintain Mean Arterial Pressure (MAP) 
<130mmHg. If facilities to monitor ICP are available then the target MAP 
reduction will be based on to maintain the Cerebral Perfusion Pressure 
(MAP-ICP) above 60mmHg. 
Non vasodilating IV antihypertensive like nicardipine, esmolol or 
labetalol are preferred. The dose should be titrated periodically to maintain 
cerebral perfusion pressure.  
 
MANAGEMENT OF INCREASED INTRACRANIAL PRESSURE 
(ICP) 58 
ICH most commonly causes raised Intra Cranial Pressure hence 
lowering it is important to prevent brainstem herniation. General measures 
to decrease ICP are control of hypertension and treatment of seizures. 
Specific measures to decrease ICP are 
 Hyperventilation following endotracheal intubation to achieve 
hypocapnea with pCO2 in the range of 25 to 30 mm Hg.  
 Use of intravenous mannitol (0.25-1 g/kg), 
 Head end elevation  
 Surgical decompression 
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SEIZURES59 
Seizures are common with lobar ICH. Antiepileptic drugs are used for 
clinical seizures. It is necessary to control seizures in such patients in order 
to prevent further increase in ICP. But prophylactic anticonvulsants use is 
not justified. 
ICH IN COAGULOPATHY 
 When clotting factors deficiency is the cause of ICH patients should 
be treated with clotting factors replacement. 
 When thrombocytopenia is the cause of ICH, patients should be 
treated with platelet transfusions. 
 Protamine sulphate in doses of 1mg for 100 units of heparin is used in 
those who develop ICH as a complication of heparin treatment.   
 For patients developing ICH as a complication of warfarin 
coagulopathy the following measures are done. 
• Warfarin should be stopped immediately 
• 5 to 25mg of Vitamin K is given IV and 
• Fresh frozen plasma (FFP) 10-20 ml/kg body weight or 
• Prothrombin complex concentrates are immediately transfused. 
• Recently recombinant factor VIIa injections have been used in 
warfarin coagulopathy related ICH.  
 Cryoprecipitates, FFP and platelet transfusions are used in ICH 
related to thrombolytic therapy. 
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DEEP VEIN THROMBOSIS (DVT) PROPHYLAXIS:  
Intermittent pneumatic compression along with elastic stockings is 
used in ICH patients to prevent DVT as a complication of prolonged 
immobilization.  
MANAGEMENT OF GLUCOSE: 
Blood glucose should be maintained in an optimal range. 
TEMPERATURE MANAGEMENT 
Hyperthermia is one of the important adverse prognostic factors in 
patients with ICH. Hence it is prudent to maintain the patient normothermic. 
ROLE OF SURGERY 60,61 
SUPRATENTORIAL ICH 
The International STICH (Surgical Trial of Intracerebral 
Haemorrhage) Trial was done to evaluate the outcome of 1033 cases of 
supratentorial ICH based on surgical and nonsurgical treatment. 
The results of this trial showed that there was no superior benefit 
documented with either of the treatment modality but superficially located 
lobar haemorrhages were an exception. Lobar haemorrhages located 
superficially < 1 cm beneath the cortex and with haematoma volume around 
20-40ml have a survival benefit from surgical evacuation of haematoma. 
STICH II trial is currently carried out to compare the outcome of surgical 
and nonsurgical treatments in superficial lobar ICH patients.  
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TREATMENT OF CEREBELLAR ICH62 
In case of cerebellar ICH there is a clear cut benefit of outcome with 
those treated surgically compared to those treated conservatively.  
 Cerebellar haematoma of size more than 3 cm in diameter definitely 
needs surgical evacuation.  
 Those with haematoma size of less than 1 cm and preserved 
consciousness without brainstem compression, there is no need of 
surgical evacuation.  
 For those with haematoma size between 1 to 3 cm, patients should be 
carefully monitored for signs of brainstem compression. 
Surgical therapy is also done as an option to decrease intra cranial 
pressure in cases of cerebellar, caudate and thalamic ICH where there is 
massive hydrocephalus.  Ventriculostomy provides drastic improvement by 
draining CSF and decreasing the intracranial tension. 
SURGERY FOR VASCULAR MALFORMATIONS 
Vascular malformations like Arterio Venous Malformations, 
cavernous angiomas and saccular aneurysms are important causes 
predisposing to ICH especially in young patients. So surgical treatment of 
these vascular malformations is important to prevent recurrent ICH in such 
patients.  
 
 
39 
 
RECURRENT ICH 
 Recurrence rate of ICH is around an average of 6%. The 
identification of cause of recurrent ICH is important. Among them the 
hypertensive bleeds are usually not associated with recurrent ICH, unless 
and otherwise there is poor control of blood pressure. AVM and cerebral 
amyloid angiopathy are associated with recurrent ICH. The site of 
recurrence of ICH also depends upon the cause of ICH. Hypertensive ICH 
presents with repeated basal ganglia bleeds. Non hypertensive   causes like 
AVM and cerebral amyloid angiopathy present with repeated lobar bleeds. 
PREVENTION OF RECURRENT ICH 
Because of the high mortality of ICH it is always important to prevent 
another episode of ICH occurring among the survivors. 
 First and foremost step is treating systemic hypertension. 
 Avoidance of excessive use of alcohol. 
 Prevention of use of sympathomimetic drugs. 
 It is important to avoid the use of antithrombotic agents in those with 
amyloid angiopathy. 
 Those with AVM or aneurysms should be treated surgically to 
prevent future recurrence. 
 But data regarding restriction of use of statins or physical activity is 
insufficient. 
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FUTURE TRENDS IN ICH TREATMENT 
Because of the limited treatment options available there is always a 
search for newer modalities of treatment for ICH. This leads to usage of 
procoagulants like the recombinant activated factor VIIa (rFVIIa).Use of 
recombinant factor VII a (rFVIIa)63 in patients presenting with ICH within 
the first four hours  slows the progression of bleeding and has been 
associated with smaller haematoma volumes  but there was no clinical 
benefit. This was evaluated in FAST trial (Factor Seven for acute 
haemorrhagic Stroke Trial). 
Recombinant factor VII a (rFVIIa)  has been used in doses of 20 and 
80 µg/kg in FAST trial. They found significant reduction in haematoma 
expansion in those treated with 80 µg/kg of recombinant factor VII a. But 
the risk of thrombo embolic complications was high. Moreover clinical 
benefits could not be documented well. So, few suggest the use of this agent 
in those showing signs of active bleed in CT Angiography like the dot sign. 
Further studies are needed regarding its use to document clear cut clinical 
benefit. 
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LIPIDS 
The lipids are essential organic components of both the plant and 
animal kingdom. They provide fuel for multicellular organisms. They are 
stored in our body mainly in the adipose tissues and around the internal 
organs. From the biochemical point of view, lipids are complex group of 
substances like fats, steroids, oils etc. They are esters of various alcohols. 
Their most important property is that they are insoluble in water. 
BIOLOGICAL SIGNIFICANCE OF LIPIDS64,65 
 Lipids provide about 9.5 grams of calories for every gram on 
combustion, there by representing a concentrated source of fuel. 
 They are important constituents of the cell membrane maintaining the 
integrity of the cells. 
 They act as thermal insulators as they are present in subcutaneous 
adipose tissue. 
 Lipids stored around the internal organs protect them from blunt 
injuries. 
 With the help of lipids, the cytoplasm of cell in separated into various 
organelles. 
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 Lipids are the backbone for synthesis of steroidal hormones, bile 
acids and many cellular messengers like prostaglandins. 
 Lipids provide essential fatty acids that are needed for normal growth. 
 They form an integral part of human nervous system helping in its 
normal functioning. 
 Vitamin A, D, E and K which are fat soluble are absorbed from the 
gut with the help of lipids. 
 Lipids are conjugated with proteins to form lipoproteins which are 
transported in plasma. 
A thorough knowledge of lipids is of prime importance as they are 
implicated in various diseases. 
Bloor’s criteria of lipids 
Bloor established certain important characteristics of lipids 
 Lipids are not soluble in water. 
 They are soluble in certain solvents like ether which are called as fat 
solvents. 
 Lipids combine with fatty acids to form esters. 
 Lipids are used by living organisms. 
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LIPIDS CLASSIFICATION 66  
1. Simple lipids - These are esters of fatty acids combined with 
alcohols.  
i) Fats: Fats are triesters of fatty acid with alcohol. Fats occurring in 
liquid form are oils. 
ii) Waxes: These are fatty acid esters formed with high molecular 
weight alcohol which are aliphatic and monohydroxy. 
2. Complex lipids:  
When esters of fatty acids have other substances along with alcohol 
and fatty acid they are called complex lipids. 
i) Phospholipids:  
Lipid substances possessing a phosphoric acid moiety along with 
fatty acid and alcohol are called phospholipids. These usually also 
contain nitrogen bases. E.g.) Lecithin- phosphatidyl choline, 
Cephalin, Sphingomyelin.   
ii) Glycolipids (glycosphingolipids):  
 These lipids have a carbohydrate residue along with special alcohol   
known as sphingosine. 
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iii) Other complex lipids: 
Sulfolipids and aminolipids have sulfate and aminoacid groups 
respectively. Lipoproteins have protein moieties in addition to lipids. 
3. Derived lipids 
These derived lipids are produced as a result of hydrolysis of simple         
or complex lipids. The substances in this category are 
 Fatty acids-unsaturated or saturated fatty acids. 
 Alcohol-straight chain alcohol, glycerol. 
 Steroids-Cholesterol and other steroidal hormones. 
 Vitamin A, D, E and K. 
CHOLESTEROL67,68 
The term cholesterol comes from a Greek word “chole steros” 
meaning “solid bile”. Cholesterol comes under the category of steroids. It is 
the most popular among steroids. Cholesterol occurs as white to yellow 
odorless granules. It is not soluble in water. 
Many Nobel prizes have so far been awarded to cholesterol 
researchers. Michael Brown and Joseph Goldstein have quoted cholesterol 
in their literature as "the most highly decorated small molecule in biology." 
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DISCOVERY 
 It was in 1769 cholesterol was first isolated.  
 Francois Poulletier de la Salle was the first to discover cholesterol in 
bile and gallstones. 
 Eugene Chevreul was the first person to understand the chemical 
components of cholesterol. 
 In 1833 Boudet isolated cholesterol from blood. 
STRUCTURE  
The molecular formula of cholesterol is C27H45OH . Its structure has a 
cyclopentanoperhydrophenanthrene nucleus. 
 
 
FIGURE.8.CHOLESTEROL STRUCTURE 
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 The molecular structure of cholesterol was discovered by Heinrich 
Wieland and Adolf Windaus. 
SOURCE OF CHOLESTEROL 
EXOGENOUS SOURCE 
Cholesterol is present in substances like milk, egg yolk, butter and 
meat i.e. mainly from animal sources. An average amount of cholesterol in 
our diet is around 0.3 gram per day. An average amount of cholesterol in a 
hen’s egg is about 250mg. 
ENDOGENOUS SOURCE 
It is also synthesized from acetyl coA inside body approximately 
around 1gram per day. 
OCCURRENCE IN BODY 
Cholesterol is distributed in many tissues predominantly in the 
nervous system. It also occurs in liver, skin, gut mucosa and endocrine 
organs especially adrenal cortex. It is found in blood and also in bile. 
CHOLESTEROL FORMS 
There are two forms of cholesterol occurring in our body the free and 
the ester forms.  
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FREE FORM 
Free cholesterol does not undergo esterification. It is the major form 
of cholesterol in human nervous system. 
ESTER FORM 
Adrenal cortex predominantly has the ester form of cholesterol. Here 
the cholesterol is esterified by combining with certain fatty acids at the C3 
position of hydroxyl group. Linoleic acid, oleic acid, palmitic acid and 
arachidonic acids are the major fatty acids that esterify with cholesterol. 
Majority of cholesterol esters are formed in plasma by the enzyme 
lecithin cholesterol acyl transferase (LCAT) that transfers acyl group from 
lecithin to cholesterol. 
LECITHIN+CHOLESTEROL                         CHOLESTEROL ESTER+    
        LYSOLECITHIN 
Tissue acyl transferases form few cholesterol esters. 
DIGESTION AND ABSORPTION 
Cholesterol is absorbed predominantly as free form from the gut 
mucosa. Pancreatic enzyme cholesterol esterase helps in hydrolysis of 
cholesterol esters releasing the free form in the intestinal lumen. But later on 
the free forms are esterified within the intestinal cell to be transported as 
  
LCAT 
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cholesterol esters in the lymph. Unsaturated fatty acids and bile salts 
promote the absorption of cholesterol. 
CHOLESTEROL METABOLISM 69,70,71,72 
SYNTHESIS69 
Although all the human tissues are capable of synthesizing 
cholesterol, it is the liver that contributes as a major organ for synthesis. 
Skin, adrenals and intestine also form cholesterol. Some amount of 
synthesis also occurs in the muscle, adipose tissue and nervous system. 
Cytoplasm and endoplasmic reticulum are the major sites of cholesterol 
synthesis within the cell. 
The carbon atoms of cholesterol are derived from Acetyl-CoA which 
is the starting molecule of cholesterol synthesis. 
1) Acetyl Co-A with the help of two enzymes thiolase and HMG CoA 
synthase forms HMG CoA (3-hydroxy-3-methylglutaryl-CoA). 
   2) HMG CoA is converted to Mevalonate with the help of HMG CoA 
reductase. This step is the rate limiting step in the biosynthesis of 
cholesterol. Various factors influence the synthesis of cholesterol acting 
on this step. It is main target of therapeutic strategy to reduce 
cholesterol with statins. 
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Insulin and thyroxine increase the enzyme’s action. While glucagon and 
glucocorticoids reduce its action. cAMP also reduces its action. This step 
requires NADPH as its cofactor. 
 
 
 
FIGURE.9.STEPS IN CHOLESTEROL SYNTHESIS 
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3) Phosphorylation of Mevalonate leads to formation of Mevalonate-5-
Phosphate then Mevalonate-5-pyrophosphate and finally Mevalonate 3 
phospho 5 pyrophosphate. 
4) Mevalonate 3 phospho 5 pyrophosphate on decarboxylation forms 
Isopentenyl pyrophosphate. 
5) Isopentenyl pyrophosphate on isomerization forms 3-3-dimethylallyl 
pyrophosphate. 
6) By a series of reactions Geranyl diphosphate and Farnesyl diphosphate 
are formed. 
7) Squalene is synthesized from two farnesyl diphosphate molecules by 
enzyme squalene synthase. Two molecules of farnesyl diphosphate 
condense at the diphosphate end to form squalene. 
8) Lanosterol is derived from squalene by cyclization. 
9) Cholesterol is formed from lanosterol by a series of steps forming        
14-desmethyl lanosterol, zymosterol and desmosterol as intermediate 
molecules, by process of demethylation and reactions involving removal 
of –CH3 group in the C14 position, shift of double bond between C8 and C9 
to C5 and C6 and saturation of the double bond in the side chain. 
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CHOLESTEROL TRANSPORT 
Dietary cholesterol is absorbed from the intestine along with other 
lipids and taken in chylomicrons and Very Low Density Lipoprotein 
(VLDL). 80-90% of absorbed cholesterol undergoes esterification in the 
lymph and transported predominantly as lipoproteins in plasma. Low 
Density lipoprotein (LDL) is the major lipoprotein carrying cholesterol to 
various tissues where it is taken up by them through the LDL receptor. Free 
cholesterol in plasma equilibrates with that in liver. 
FACTORS INFLUENCING SERUM CHOLESTEROL LEVELS 
Normal serum cholesterol varies from individual to individual         
[average of 200mg/dl is taken as cutoff value]. Numerous factors influence 
the serum cholesterol levels. 
1. DIETARY LIPIDS68 
Increased consumption of lipids especially saturated fatty acids 
increases the cholesterol synthesis. Poly unsaturated fatty acids in diet help 
to lower the serum cholesterol levels. 
2. DIETARY CARBOHYDRATES 
High intake of carbohydrates especially sucrose and fructose raise the 
serum cholesterol level. 
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3. HEREDITY  
Genetic factors play a major role in serum cholesterol level variations. 
4. BLOOD GROUPS 
Blood group A individuals have higher serum cholesterol compared 
to those with group B or O. 
5. DIETARY FIBRES 
Increased intake of dietary fibers decreases the serum cholesterol by 
facilitating excretion of cholesterol and bile acids. 
6. VITAMINS 
Niacin in large amounts lowers serum cholesterol. Few animal studies 
have revealed that pyridoxine deficiency increases cholesterol level. 
7. EXERCISE 
Certain population studies have revealed that strenuous exercise 
decreases the cholesterol levels in serum. 
FATE OF CHOLESTEROL  
Most of the cholesterol in the body is eliminated in bile as free form 
or by conversion to bile acids. Cholic acid and chenodeoxy cholic acid are 
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the primary bile acids that are synthesized in the liver from cholesterol. 
They are then conjugated with glycine and taurine to be excreted in bile. 
These exist as salts in bile called bile salts. Some of the primary bile acids 
are converted to secondary bile acids deoxycholic acid and lithocholic acid 
by the gut bacteria. The bile acids undergo enterohepatic circulation and 
majority of them are reabsorbed in the terminal part of ileum. It is only a 
portion of the bile salts that is excreted in feces which is still the major route 
of cholesterol excretion. 
OTHER FATES OF CHOLESTEROL 
1. The adrenocortical hormones glucocorticoids and mineralocorticoids 
are derived from cholesterol. 
2. 7-dehydrocholesterol in skin is converted to Vitamin D by ultraviolet 
rays which then by a series of reactions in liver and kidney is 
converted into active form of Vitamin D. 
3. Sex hormones like androgens, estrogens and progesterones are 
formed from cholesterol. 
4. Cholesterol in large intestine is converted to coprostanol and excreted 
in feces. 
5. Cholesterol is important component of the cell membrane helping in 
cellular repair and proliferation. 
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LIPOPROTEINS73,74,75 
The major vehicle of transportation of lipids in plasma is via 
lipoproteins. The main lipid groups found in lipoproteins are: 
1. Cholesterol ester 
2. Phospholipids  
3. Triacylglycerol 
4. Cholesterol esters 
5. Unesterified fatty acids (free fatty acids) 
Free fatty acids are the most active plasma lipids. 
STRUCTURE73  
 
 
FIGURE 10.STRUCTURE OF LIPOPROTEIN 
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The structure of lipoprotein consists of hydrophobic core made up of 
nonpolar triacylglycerol and cholesterol esters. This is next enveloped by 
amphipathic phospholipids with their polar ends facing outside towards 
plasma. These are also complexed with apoproteins to form lipoprotein. As 
the content of lipid in the lipoprotein increases there is a decrease in the 
density of lipoprotein. 
THE MAIN LIPOPROTEIN CLASSES ARE  
1. Chylomicrons 
2. Chylomicron Remnants 
3. Very Low Density Lipoprotein(VLDL) 
4. Intermediate Density Lipoprotein (IDL) 
5. Low Density Lipoprotein(LDL) 
6. High Density Lipoprotein(HDL) 
The various classes of lipoproteins are arranged in decreasing order of 
size and in increasing order of their densities. Chylomicrons being the 
largest but least dense but HDL-C is the smallest in size with high density. 
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FIGURE.11.LIPOPROTEIN CLASSES 
ELECTROPHORETIC CLASSIFICATION 
Fredrickson classified lipoproteins based on their electrophoretic 
motility. Paper and agarose gel are most commonly used media.  
The lipoproteins are classified as  
• Origin- Chylomicrons 
• Pre-β lipoprotein-VLDL 
• β  lipoprotein –LDL,IDL 
• α lipoprotein –HDL 
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TABLE.3.LIPOPROPROTEIN CHARACTERISTICS 
CLASS DENSITY (g/ml) 
ELECTRO-
PHORESIS SOURCE 
CHIEF 
LIPID APOPROTEIN 
Chylomicron < 0.95 Origin Intestine 
85% 
Triglyceride 
(TGL) 
B48, AI, AIV 
(E, CI, CII, 
CIII—by 
transfer from 
HDL) 
Chylomicron 
remnants <1.006 Origin Intestine 
60% TGL, 
20% CHOL B48, E 
VLDL <1.006 Pre-β Liver 55% TGL, 20% CHOL 
B100, E, CI, 
CII, CIII 
IDL 1.006-1.019 
β Derived 
from 
VLDL 
35% CHOL, 
25% TGL B100, E 
LDL 1.019-1.063 
β Derived 
from IDL 
60% CHOL, 
5% TGL B100 
HDL 1.063-1.21 α 
Liver, 
intestine, 
plasma 
25%  PL 
20% CHOL, 
5% TGL 
50%-protein 
AI, AII, CI, CII, 
CIII, E 
HDL2 
1.063-
1.125 
α 
      
HDL3 1.125-1.21 
α 
      
Lp(a) 1.05-1.09 
α 
Liver 60% CHOL 5% TGL B100, apo(a) 
 
Very Low Density Lipoprotein (VLDL); 
Intermediate Density Lipoprotein (IDL); 
Low Density Lipoprotein (LDL); 
High Density Lipoprotein (HDL) 
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CHOL-Cholesterol; 
TGL-Triglyceride 
 PL-Phospholipids 
METABOLISM OF  LIPOPROTEINS 75 
 
 
FIGURE.12.METABOLISM OF LIPOPROTEINS 
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SOURCES OF LIPOPROTEINS 
1. Chylomicrons are obtained as a result of absorption of the triacylglycerol 
from intestine (i.e. exogenous). 
 2. VLDL is obtained by endogenous synthesis in liver. 
3. LDL is obtained as a result of degradation of VLDL. 
4. HDL is obtained from synthesis in liver and intestinal cells. 
TRANSPORT OF TRIACYLGLYCEROL 
Chylomicrons are the major vehicle of transportation of exogenous 
triacylglycerol that is absorbed from intestine as a result of fat digestion. 
They are seen in the chyle of the intestinal lymphatics transporting lipids of 
dietary origin to the circulation. VLDL is the major carrier of endogenous 
triacylglycerol from liver to other tissues.   
The chylomicrons initially have apo B48, apo AI and apo AIV. They 
later on get the apo E and apo C components from HDL in plasma. VLDL 
initially has apo B100, apo E and some apo C. They later on get apo E and 
apo C components from HDL in plasma.  
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CATABOLISM  
Shortly after their formation the chylomicrons and VLDL undergo 
rapid catabolism and form chylomicron remnants and IDL respectively. 
Most of the fatty acids that are brought by catabolism of the triacylglycerol 
are taken to the adipose tissue, skeletal and cardiac muscles while some go 
to liver.  
THE ACTION OF LIPOPROTEIN LIPASE 
Lipoprotein lipase situated in the capillary wall is attached to the 
endothelium with the help of heparan sulphate. Hepatic lipase is situated in 
the liver cells at the surface of sinusoids. The important cofactors needed for 
the action of these enzymes are phospholipid and apo CII  but apo A II and 
apo CIII are the inhibitors of this enzyme. Lipoprotein lipase hydrolyses the 
lipoproteins especially the triacylglycerol into diacylglycerol then to 
monoacylglycerol and ultimately form free fatty acids and glycerol. Among 
the free fatty acids, few enter the circulation while a great amount of fatty 
acids are taken to other tissues. 
The fatty acids from VLDL are taken to fat cells by binding to the 
VLDL receptor. The synthesis of lipoprotein lipase in adipose tissue is 
increased by insulin.   
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The lipoprotein lipase acting on chylomicrons removes most of 
triacylglycerol and apo C retaining apo E resulting in formation of 
chylomicron remnants which have higher content of cholesterol and their 
esters. In the same manner, VLDL is metabolised to form VLDL remnant 
i.e. IDL (INTERMEDIATE DENSITY LIPOPROTEIN). 
THE REMNANT LIPOPROTEINS UPTAKE 
The major organ that plays role in the remnant lipoprotein uptake is 
liver. This is by receptor mediated endocytosis. After that the cholesterol 
esters and remaining triacylglycerol are catabolised. Hepatic lipase plays a 
role in this step. Receptor mediated endocytosis of IDL occurs in liver and 
leads to formation of LDL.  
CATABOLISM OF LDL 
The most important step in metabolism of LDL is its uptake by liver 
(70%) and extrahepatic tissues (30%) by LDL receptor (apo B100, apo E ) . 
LDL is the major carrier of cholesterol from liver to extrahepatic cells. 
Because of this LDL is considered as bad cholesterol promoting 
atherogenesis . Based on the hepatic influx of free fatty acids the synthesis 
of LDL is increased. Any defect in the LDL receptor that reduces its action 
causes decreased catabolism of LDL increasing its plasma levels. 
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HDL METABOLISM76 
HDL is mainly synthesized by liver. It has apo C and apo E which are 
important in the catabolism of both chylomicrons and VLDL. Initially 
formed HDL is discoidal with phospholipids, apo A and cholesterol. The 
binding of lecithin cholesterol acyltransferase (LCAT) and apo AI, the 
activator of LCAT to the discoidal HDL helps in conversion of free 
cholesterol to cholesterol esters and lysolecithin. This leads to formation of 
nonpolar lipid core and polar groups outside there by changing the HDL 
form to spherical and pseudo micelle type. 
Scavenger receptor B 1(SRB1) is the HDL receptor77, 78. SRB1 
receptor in liver binds to HDL and causes transfer of cholesterol esters to 
the hepatocytes. In extrahepatic tissues it modifies HDL making it a major 
acceptor of cholesterol thereby transporting cholesterol from other tissues to 
liver. This cholesterol is later on excreted into bile. Hence HDL is called 
good cholesterol. This process is known as reverse cholesterol transport. 
HDL-C is hence anti atherogenic. 
It is HDL3 that is initially formed; this is converted to less dense 
HDL2 after it accepts the extrahepatic cholesterol through SRB1 receptor. 
Later on HDL3 is formed again by HDL2 hydrolysis.The transformation 
between HDL 3 and HDL2 is known as HDL cycle. Pre β HDL is formed 
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after apo AI is released and some amount of phospholipids and cholesterol 
are added. 
 ATP binding cassette transporters A1 [ABCA1]   & G1 [ABCG1] 
mediate another important mechanism in the process of reverse 
cholesterol transport.  
 Cholesterol Ester Transfer Protein (CETP) transfers cholesteryl esters 
from HDL to the lower density lipoproteins.CETP has a major role in 
lipid metabolism and can influence the process of atherogenesis.  
Because of the reverse cholesterol transport HDL when present in 
higher concentrations exert anti atherogenic effect decreasing the incidence 
of   coronary artery heart disease. HDL also has antioxidant property. 
ROLE OF LIPIDS IN DISEASES79 
 Elevated serum cholesterol had been established as a major risk factor 
in the pathogenesis of atherosclerosis and hence associated with 
increased incidence of ischemic heart disease and cerebral infarction. 
 Diseases like diabetes, hypothyroidism and renal diseases which are 
characterized by secondary hyperlipidemia also accelerate 
atherosclerosis.  
 HDL-Cholesterol is known for its negative correlation76 with 
atherosclerosis because of its reverse cholesterol transport.  
 Fredrickson classified the primary hyperlipoproteinemias into five 
different classes based on the major classes of lipoproteins elevated 
and different genetic mutations.
FIGURE.13.     HYPERLIPOPROTEINEMIAS FREDRICKSON
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CLASSIFICATION 
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SECONDARY HYPERLIPIDEMIAS 
 Diabetes mellitus 
 Hypothyroidism 
 Renal diseases like nephrotic syndrome and end stage renal disease  
 Hepatitis and cholestasis 
 Cushing’s syndrome 
 Lysosomal storage disorders 
 Estrogen and certain drugs like steroids and thiazides.  
The above mentioned conditions are associated with elevation of 
various lipid levels promoting atherogenesis. There are many classes 
of lipid lowering agents used in clinical practice to control 
hyperlipidemias.  
LIPID LOWERING DRUGS                             INDICATIONS 
 HMG-CoA Reductase Inhibitors (Statins):        Elevated LDL-C 
Atorvastatin, Lovastatin, Simvastatin, 
 Pravastatin. 
 Bile acid sequestrants:                                        Elevated LDL-C 
Cholestyramine, Colestipol 
 Fibric acid derivatives                                        Elevated TGL 
Gemfibrozil,Fenofibrate 
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    LIPID LOWERING DRUGS                            INDICATIONS 
 Nicotinic acid                                 Low HDL-C;  
                                                                      Elevated TGL; LDL-C 
 Omega 3 fatty acids                                      Elevated TGL 
 Cholesterol absorption inhibitors            Elevated LDL-C 
Ezetimibe  
DISORDERS ASSOCIATED WITH HYPOLIPIDEMIAS 
Few conditions are associated with low levels of certain lipid fractions. 
They are frequently inherited causes. Few are mentioned below. 
I) CONDITIONS WITH LOW LEVELS OF APOB LIPOPROTEINS 
Familial Hypobetalipoproteinemia  
Low plasma levels of LDL-C due to mutations in apoB. 
PCSK9 [proprotein convertase subtilisin/kexin type 9] Deficiency 
Loss of function mutation of PCSK9 with low levels of LDL-C.  
Abetalipoproteinemia 
Abetalipoproteinemia  is due to mutation in microsomal triglyceride transfer 
protein gene resulting in low cholesterol, triglycerides and  β lipoproteins.  
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II) INHERITED CAUSES OF LOW LEVELS OF HDL-C 
Gene Deletions and Mutations in Apo A-I 
Tangier’s Disease  
Mutations in the gene encoding ABCA1  
LCAT Deficiency 
Due to deficiency of lecithin cholesterol acyl transferase there is 
impaired maturation of HDL.  
Primary Hypoalphalipoproteinemia 
It is characterized by low HDL-C.  
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NATIONAL CHOLESTEROL EDUCATION PROGRAM ATP III 
GUIDELINES FOR MANAGEMENT OF LIPID DISORDERS80,81,82 
 TOTAL CHOLESTEROL 
 <200 mg/dl  - Desirable 
 200-239 mg/dl  - Borderline high 
 ≥240 mg/dl  - High 
 
 LDL CHOLESTEROL  
 <100 mg/dl  - Optimal 
 100-129 mg/dl  - Near optimal 
 130-159 mg/dl  - Borderline high 
 160-189 mg/dl  - High 
 ≥190 mg/dl  - Very high 
 TRIGLYCERIDES 
 <150 mg/dl  - Normal 
 150-199 mg/dl  - Borderline high 
 200-499 mg/dl  - High 
 ≥500 mg/dl  - Very high 
 HDL CHOLESTEROL 
 <40 mg/dl  - Low 
 ≥60 mg/dl  - High 
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LOW CHOLESTEROL AND INTRACEREBRAL HAEMORRHAGE 
Many population based studies like the MRFIT study and 
HONOLULU HEART PROGRAM have shown that low serum cholesterol 
is associated with intracerebral haemorrhage. This paradox of inverse 
association of serum cholesterol and ICH is more pronounced with 
cholesterol levels especially when less than 160mg% according to the 
MRFIT study. 
The proposed theory for this inverse association is as follows. 
Cholesterol and triglycerides are needed for normal cell membrane integrity 
especially the vascular endothelial cells. Low levels of these lipids may 
cause increased erythrocyte fragility and weakening of the capillary 
endothelium leading to micro aneurysms and promote intracerebral 
haemorrhage especially in those with systemic hypertension. This inverse 
association of serum lipids with ICH forms the background of our study. 
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MATERIALS AND METHODS 
SOURCE OF DATA 
 A total number of 50 patients who presented with Intracerebral 
Haemorrhage  during the study period from December 2013 to August 2014 
in Thanjavur Medical College Hospital and who fulfilled the inclusion 
criteria were taken for the study. 
PLACE OF STUDY:  
Thanjavur Medical College Hospital, Thanjavur. 
STUDY DESIGN: 
Single centre hospital based prospective observational study. 
INCLUSION CRITERIA:   
Patients admitted in Thanjavur Medical College Hospital with 
Intracerebral Haemorrhage (ICH). 
EXCLUSION CRITERIA: 
1. Traumatic Intracerebral Haemorrhage.(ICH) 
2. Subarachnoid haemorrhage 
3. Tumour Bleed 
4. Use of Anticoagulants, Use of Antiplatelets, Use of Statins. 
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5. Intracranial Aneurysm, AV Malformations 
6. Sympathomimetics abuse 
7. History of  bleeding diathesis 
8. Patients with thrombocytopenia 
METHODS OF COLLECTION OF DATA: 
 50 patients with Intracerebral Haemorrhage satisfying inclusion 
criteria admitted in Thanjavur Medical College Hospital from December 
2013 to August 2014 were taken for the study after excluding those who had 
features given in exclusion criteria. After obtaining consent, history, clinical 
examination and investigations were done. 
Diagnosis of Intracerebral haemorrhage was made in patients based 
on history, clinical features and plain non contrast CT scan of Brain. 
INVESTIGATIONS DONE 
1) Blood sugar 
2) Blood urea 
3) Serum creatinine 
4) Serum electrolytes- Sodium and potassium  
5) Urine albumin, sugar and deposits 
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6) Complete haemogram including  
• Haemoglobin, 
• Total WBC count, differential counts, 
• Red cell count, 
• Platelet count, 
• Peripheral smear  
• Erythrocyte Sedimentation Rate (ESR) 
• Bleeding time, Clotting time,  
• Prothrombin Time and Activated Partial Thromboplastin 
Time (PT, aPTT)  
        7) Fasting Lipid Profile-  
Total Cholesterol (TC),  
Low density cholesterol    (LDLc),  
High density cholesterol (HDLc) , 
Very Low density cholesterol (VLDLc) and  
Triglycerides (TG) 
        8) ECG 
        9) CT Brain 
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       10) Other investigations like MRI brain with MR angiography, 
Ultrasound abdomen, Chest X ray, Echocardiography and Liver Function 
Tests were taken   . 
LIPID PROFILE ESTIMATION 
Blood was collected for lipid profile estimation from the ICH patients 
within 24 to 48 hours of onset of disease. The sample was collected after 9 
to 12 hours of fasting. 
The serum was separated and was subjected to centrifugation .The 
supernatant was taken out and subjected for analysis. 
ESTIMATION OF CHOLESTEROL 
Serum cholesterol was estimated by the calorimetric method 
CHOD-POD. It is based on the principle that cholesterol produces a 
coloured complex during the CHOD-POD reaction and the absorbance of 
the coloured complex assessed by calorimeter is directly proportional to the 
concentration of cholesterol in that sample. 
 
Cholesterol Ester +Water                 Cholesterol + Fatty Acid 
Cholesterol +Oxygen                   4-Cholestenone +H2O2 
2H2O2+4-Aminoantipyrine + Phenol                   Q uinoneimine dye+4H2O 
CHO
POD 
CHE 
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CHE-Cholesterol Esterase 
CHOD-Cholesterol Oxidase 
POD-Peroxidase 
Absorbance of Sample    X Standard concentration = mg/dL cholesterol 
 
Absorbance of Standard 
ESTIMATION OF HIGH DENSITY CHOLESTEROL (HDL-C) 
It is based on the principle that  very low density (VLDL) and low 
density (LDL) cholesterol in the sample are precipitated when mixed with 
phosphotungstic acid along with magnesium ions and on subjecting to 
centrifugation the concentration of HDL cholesterol can be determined in 
the sample by calorimetric method. 
Abs of Sample × Standard concentration× dilutional factor = HDL–C in mg/dl 
 
Abs of Standard     
ESTIMATION OF TRIGLYCERIDES (TGL) 
The sample to be tested for triglycerides is treated with 
lipoproteinlipase (LPL) where it gives glycerol and free fatty acids. By the 
action of glycerol kinase and ATP glycerol is converted to glycerol-3-
phosphate (G3P) and adenosine-5-diphosphate (ADP).  
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Glycerol phosphate dehydrogenase [GPO] converts Glycerol-3-
phosphate [G3P] to dihydroxyacetone phosphate [DAP] and hydrogen 
peroxide [H2O2]. Peroxidase [POD] catalyses the reaction of hydrogen 
peroxide [H2O2] with 4-aminophenazone and p-chlorophenol to form 
coloured compound. 
 
 
The absorbance of the coloured complex assessed by calorimeter is 
directly proportional to the concentration of triglycerides in that sample. 
Absorbance of Sample X Standard concentration = mg/dL TGL in sample 
 
Absorbance of Standard 
ESTIMATION OF LDL-CHOLESTEROL  
The Friedewald Formula is used for indirect estimation of serum LDL. 
LDL cholesterol = Total cholesterol – [HDL +TGL] 
                                                     5 
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ESTIMATION OF VLDL-C 
VLDL-C = TRIGLYCERIDE  
                            5 
The details of the patient like history, clinical examination and 
investigations were collected and entered in a proforma sheet. The model of 
the proforma used has been enclosed as an annexure. 
ANALYSIS: 
The statistical analysis of   the data collected from the patient was done 
using SPSS (Statistical Package for Social Sciences) software. 
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OBSERVATION AND RESULTS 
TABLE.4. AGE DISTRIBUTION IN PATIENTS 
 
AGE NO.OF PATIENTS (N=50) 
PERCENTAGE 
(100%) 
Below 40 yrs 2 4.0 
40 to 59 yrs 20 40.0 
60 to 79 yrs 24 48.0 
Above 80 yrs 4 8.0 
 
 
FIGURE.14.AGE DISTRIBUTION IN PATIENTS 
 
 
 
The mean age group of this study is 59.1 (± 12.61) years. 
In this study among the 50 patients of Intracerebral Haemorrhage ,  
48% belong to age group of 60-79years 
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40% belong to age group of 40-59years.  
8% belong to above 80 years. 
4% belong to below 40 years. 
 
TABLE.5.SEX DISTRIBUTION IN PATIENTS 
 
SEX NO.OF PATIENTS (n=50) 
PERCENTAGE 
(100%) 
Male 35 70.0 
Female 15 30.0 
 
 
FIGURE.15.SEX DISTRIBUTION IN PATIENTS 
 
 
 
70% of ICH patients in our study are males; 
30 % of ICH patients are females in our study. 
The male: female ratio is 2.3: 1. 
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TABLE.6.AGE AND SEX DISTRIBUTION OF ICH 
 
 
AGE MALES FEMALES 
Below 40 yrs 
2 0 
40 to 59 yrs 
15 5 
60 to 79 yrs 
16 8 
Above 80 yrs 
2 2 
 
 
FIGURE.16.AGE AND SEX DISTRIBUTION IN PATIENTS 
 
 
 
 
The mean age group among the male patients with ICH was 58 years. 
The mean age group among the female patients with ICH was 62 years. 
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TABLE.7.SITE OF ICH DISTRIBUTION 
 
 
 
 
FIGURE.17.SITE OF ICH DISTRIBUTION 
 
 
 
Basal ganglia constitutes the most common site of ICH in our study, 
contributing to 56% of cases. 
Lobar ICH is the second most common site accounting for 22% of patients. 
Thalamic haemorrhage contributes to about 14% of patients. 
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SITE OF ICH NO.OF PATIENTS (N=50) 
PERCENTAGE 
(100%) 
BASAL GANGLIA 28 56.0 
LOBAR 11 22.0 
THALAMUS 7 14.0 
CEREBELLUM 3 6.0 
PONS 1 2.0 
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Cerebellar bleeds were 6 % of the total cases. 
Pons was the site of ICH only in 2 % of study group. 
 
TABLE.8. SHT IN PATIENTS  
 
SHT NO.OF PATIENTS (N=50) 
PERCENTAGE 
(100%) 
Yes 40 80.0 
No 10 20.0 
 
 
FIGURE.18.SHT IN PATIENTS 
 
 
 
A clear majority of ICH patients around 80% are hypertensives in our study. 
Only 20% of the patients are non hypertensives. 
Yes 80%
No 20%
Yes
No
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TABLE.9.BP STAGE IN PATIENTS 
 
BP STAGE 
(mmHg) 
NO.OF RESPONDENTS 
(N=50) 
PERCENTAGE 
(100%) 
Below 140/90 10 20.0 
140/90 to 159/99 5 10.0 
Above 160/100 35 70.0 
 
 
FIGURE.19.BP STAGE IN PATIENTS 
 
 
 
 
Around 70% of the total ICH patients   in our study had Stage II 
hypertension (BP ≥ 160/100 mmHg). 
10% of patients had Stage I hypertension (BP 140/90 -159/99 mm Hg). 
As mentioned earlier 20% had BP <140/90 mmHg. 
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TABLE.10.DM IN ICH PATIENTS 
 
 
DM NO.OF PATIENTS (N=50) 
PERCENTAGE 
(100%) 
Yes 17 34.0 
No 33 66.0 
 
 
 
FIGURE.20.DM IN ICH PATIENTS 
 
 
 
 
 
Only 34 % of patients in our study had diabetes mellitus. 
 66% did not have diabetes mellitus. 
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TABLE.11.ALCOHOL CONSUMPTION IN PATIENTS 
 
ALCOHOL NO. OF PATIENTS (n=50) 
Percentage 
(100%) 
Yes 29 58.0 
No 21 42.0 
 
 
FIGURE.21.ALCOHOL CONSUMPTION IN PATIENTS 
 
 
 
58% of patients in our study had history of alcohol consumption. 
 42% of the patients were non alcoholics. 
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TABLE.12.SMOKING IN PATIENTS 
 
 
SMOKING NO.OF PATIENTS (N=50) 
PERCENTAGE 
(100%) 
Yes 24 48.0 
No 26 52.0 
 
 
FIGURE.22.SMOKING IN PATIENTS 
 
 
 
About 52% of patients in our study group are nonsmokers. 
Only 48% of patients in our study are smokers. 
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TABLE.13.OUTCOME OF ICH PATIENTS 
 
 
OUTCOME NO.OF PATIENTS (n=50) 
PERCENTAGE 
(100%) 
Alive 19 38.0 
Dead 31 62.0 
 
 
FIGURE.23.OUTCOME OF ICH PATIENTS 
 
 
 
Among our ICH patients about 62% died. 
 
Remaining 38% are alive. 
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TABLE.14.TOTAL CHOLESTEROL IN PATIENTS 
 
 
TOTAL 
CHOLESTEROL 
(mg/dl) 
NO OF 
PATIENTS 
(n=50) 
PERCENTAGE 
(100%) 
< 200 36 72.0 
200 to 239 11 22.0 
≥ 240 3 6.0 
 
 
FIGURE.24.TOTAL CHOLESTEROL IN PATIENTS 
 
 
 
 
A clear majority of patients around 72% in our study group had serum 
total cholesterol < 200mg/dl. 
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22% of patients had their serum total cholesterol within range of 200-
239 mg/dl. 
Only 6 % of patients in our study had their serum cholesterol ≥ 240 
mg/dl. 
The mean total serum cholesterol of this study group was 
168.09±43.74 mg/dl. 
To test the statistical significance of this relation we did a t-Test 
taking 200mg/dl as a normal total cholesterol for normal population. 
The study population was partitioned into two groups with this cut off. 
TABLE.15.T-TEST FOR TOTAL-CHOLESTEROL 
TOTAL-C 
IN mg/dl MEAN S.D 
STATISTICAL 
INFERENCE 
< 200 
(n=36) 145.9528 
t-TEST 
26.93186 
T=-9.915 Df=48 
 
P value= .000<0.05 
 
statistically significant ≥200 (n=14) 225.0000 20.31672 
 
 
36 ICH patients in our study had their serum total cholesterol 
<200mg/dl and their mean total cholesterol was 145.95 mg/dl. 
  14 ICH patients in our study had their serum total cholesterol 
≥200mg/dl and their mean total cholesterol was 225 mg/dl. 
Using t test, there is statistically significant difference between two 
means (P value <0.05). 
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TABLE.16.TRIGLYCERIDES IN PATIENTS 
 
TRIGLYCERIDES 
IN mg/dl 
NO.OF PATIENTS 
(N=50) 
PERCENTAGE 
(100%) 
< 150 37 74.0 
150 to 199 10 20.0 
≥ 200 3 6.0 
 
 
FIGURE.25.TRIGLYCERIDES IN PATIENTS  
 
 
 
74% of patients in this study had their serum triglycerides level <150 mg/dl. 
20% of patients had levels from 150-199 mg/dl. 
6% of patients had levels ≥ 200 mg/dl. 
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The mean serum triglyceride among the study population was 124.12±50.76 
mg/dl. 
To test the statistical significance of this relation we did a t-Test 
taking 150 mg/dl as a normal triglyceride level for normal population. 
The study population was partitioned into two groups with this cut 
off. 
TABLE.17.T-TEST FOR TRIGLYCERIDES 
 
TGL 
IN mg/dl MEAN S.D 
STATISTICAL 
INFERENCE 
< 150 (n=37) 100.757 29.009 T=-8.763 Df=48 
 
P value= .000<0.05 
 
Statistically Significant  
≥ 150 (n=13) 
190.615 39.010 
 
 
37 ICH patients in our study had their serum triglyceride < 150 mg/dl and 
their mean triglyceride was 100.76 mg/dl. 
13 ICH patients in our study had their serum triglyceride ≥ 150 mg/dl and 
their mean triglyceride was 190.62 mg/dl. 
Using t test, there is statistically significant difference between the two 
means (P value <0.05). 
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TABLE.18. HDL CHOLESTEROL IN PATIENTS 
 
 
HDL CHOLESTEROL 
IN mg/dl 
No.of PATIENTS 
(n=50) 
Percentage 
(100%) 
< 40 38 76.0 
40 to 59 9 18.0 
≥ 60 3 6.0 
 
 
FIGURE.26.HDL CHOLESTEROL IN PATIENTS 
 
 
76% of patients in our study had their serum HDL-C < 40 mg/dl. 
18% of patients had levels from 40-59 mg/dl. 
6% of patients had levels ≥ 60 mg/dl. 
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The mean HDL-Cholesterol level in the study population is 32.45± 15.30 
mg/dl. 
 
To test the statistical significance of this relation we did a t-Test 
taking 40 mg/dl as a normal HDL cholesterol for normal population. 
The study population was partitioned into two groups with this cut off. 
TABLE.19.T- TEST FOR HDL CHOLESTEROL  
 
 
HDL-C 
IN mg/dl 
MEAN S.D STATISTICAL INFERENCE 
< 40 (n=38) 25.683 9.007 T = -9.082 Df = 48 
P value=.000<0.05 
Statistically Significant ≥ 40 (n=12) 53.883 10.525 
 
38 ICH patients in our study had their serum HDL < 40 mg/dl and their 
mean HDL was 25.68 mg/dl. 
12 ICH patients in our study had their serum HDL ≥ 40 mg/dl and their 
mean HDL was 53.88 mg/dl. 
Using t test, there is statistically significant difference between the two 
means (P value <0.05). 
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TABLE.20.VLDL CHOLESTEROL IN PATIENTS 
 
 
VLDL CHOLESTEROL 
IN mg/dl 
NO OF PATIENTS 
(n=50) 
PERCENTAGE 
(100%) 
< 30 36 72.0 
≥ 30 14 28.0 
 
 
FIGURE.27.VLDL CHOLESTEROL IN PATIENTS 
 
 
72% of ICH patients in our study had VLDL <30mg/dl. 
28% of patients had their levels ≥ 30 mg/dl. 
The mean VLDL-Cholesterol in our study population was 25.25± 10.14 
mg/dl. 
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To test the statistical significance of this relation we did a t-Test 
taking 30 mg/dl as a normal VLDL cholesterol for normal population. 
The study population was partitioned into two groups with this cut off.  
 
TABLE.21.T-TEST FOR VLDL CHOLESTEROL  
 
 
VLDL-C 
IN mg/dl MEAN S.D 
STATISTICAL 
INFERENCE 
< 30 (n=36) 20.408 5.977 T=-8.471 Df=48 
 
P value= .000<0.05 
 
Statistically Significant  
≥ 30 (n=14) 37.714 7.650 
 
 
36 ICH patients in our study had their serum VLDL < 30 mg/dl and their 
mean VLDL was 20.41 mg/dl. 
14 ICH patients in our study had their serum VLDL ≥ 30 mg/dl and their 
mean VLDL was 37.71 mg/dl. 
Using t test, there is statistically significant difference between the two 
means (P value <0.05). 
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TABLE.22. LDL CHOLESTEROL IN PATIENTS 
LDL CHOLESTEROL 
IN mg/dl 
NO.OF PATIENTS 
(N=50) 
PERCENTAGE 
(100%) 
< 100 22 44.0 
100 to 129 12 24.0 
130 to 159 9 18.0 
160 to 189 6 12.0 
≥190 1 2.0 
 
 
FIGURE.28.LDL CHOLESTEROL IN PATIENTS 
 
 
 
In our study serum LDL-cholesterol was  
<100mg /dl in 44 % of the ICH patients, 
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100-129mg/dl in 24 % of patients, 
130-159mg/dl in 18% of patients, 
160-189mg/dl in 12% of patients, 
≥190 mg/dl in 2 % of patients. 
The mean LDL-Cholesterol level in our study population was 
108.26± 43.31mg/dl. 
To test the statistical significance of this relation we did a t-Test 
taking 130mg/dl as a normal LDL cholesterol cut off for normal population. 
The study population was partitioned into two groups with this cut off. 
TABLE.23.T-TEST FOR LDL CHOLESTEROL  
LDL-C MEAN S.D 
STATISTICAL 
INFERENCE 
<130 
(n=34) 84.6876 26.70511    T=-9.281 Df=48 
 
P value= .000<0.05 
 
Statistically Significant 
≥ 130 
(n=16) 
158.3375 24.97174 
 
34 ICH patients in our study had their serum LDL cholesterol  
< 130mg/dl and their mean LDL cholesterol was 84.69 mg/dl. 
16 ICH patients in our study had their serum LDL cholesterol 
 ≥ 130mg/dl and their mean LDL cholesterol was 158.34 mg/dl. 
Using t test, there is statistically significant difference between the two 
means (P value <0.05). 
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DISCUSSION 
In this study, 50 cases of Intracerebral Haemorrhage (ICH) were 
included as per the inclusion and exclusion criteria, the observations were 
recorded and results were compared with other similar studies. 
AGE DISTRIBUTION  
 The mean age group of ICH patients in our study was 59.1 (± 12.61) 
years.  
 It is in comparison with Iribarren et al49 where the mean age was 54.2 
years and Broderick et al83 where the mean age was 64.8± 16.1 years. 
 Comparing with Indian studies the mean age group was 59.7±14 
years in a study from Calicut Ashraf V. Valappil et al84 and 57.32 ± 
12.84 years in a study from AIIMS by Rohit Bhatia et al85. 
 Majority of the patients (48%) belonged to age group of 60-79years in 
our study. This observation was similar to that in a study from 
JIPMER Narayan et al86 where about 46 % of patients were in 60-79 
years group.  
SEX DISTRIBUTION 
 70% of ICH patients in our study are males; 
 30 % of ICH patients are females in our study. 
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 The male: female ratio in our study is 2.3: 1. 
 This ratio is similar to Ashraf V. Valappil et al84 with ratio of 2.08:1 
and Rohit Bhatia et al85 where the ratio was 1.9:1. 
 
SITE OF ICH 
 Basal ganglia is the common site of ICH in our study contributing to 
56% of cases. 
 This is in accordance with Thrift et al87 in which basal ganglia is the 
most common site of ICH. 
 This is also in concordance with Indian studies,  Ashraf V. Valappil et 
al84 and Narayan et al86  where basal ganglia was the most common 
site but the percentages were slightly lower 49% and 45% 
respectively. 
RISK FACTORS AND ICH 
SYSTEMIC HT AND ICH 
 A clear majority around 80% of ICH patients, are hypertensives in 
our study. Around 70% of the total ICH patients in our study had 
Stage II hypertension (BP ≥ 160/100 mmHg). 
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 Similar trends were seen in Broderick & Brott et al88 where 73% of 
ICH patients had systemic hypertension 
 In Ashraf V. Valappil et al84  76% of ICH  patients had hypertension. 
DM AND ICH 
 Only 34 % of patients in our study had diabetes. 
 In a study done in Sweden89 also around 37% of ICH patients had 
diabetes. Similar results were seen in Ashraf V. Valappil et al84  
where  38% had diabetes. 
ALCOHOL AND ICH 
 58% of patients in our study had history of significant alcohol 
consumption. Similarly in Quereshi et al9 alcohol consumption was 
significant in ICH patients.  
 But lesser percent (21%) of ICH patients in Calicut study  Ashraf V. 
Valappil et al84  had significant alcohol consumption.  
SMOKING AND ICH 
 Only 48% of patients in our study had history of smoking. It is 
somewhat lesser compared to western studies Iribarren et al49 where it 
was 56.25%. In Indian study Ashraf  V. Valappil et al84 , around 36% 
of patients had history of smoking. 
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MORTALITY IN ICH 
 Among our ICH patients about 62% died.  
 The mortality rate in Joseph P. Broderick al90., was around 42%. 
 In India the motality rate in Shyamal Kumar Das et al91 was around 
48% and in Narayan et al86  the rate was 50% . 
LIPID PROFILE AND ICH 
SERUM TOTAL CHOLESTEROL AND ICH 
 A clear majority of patients around 72% in our study group, had 
serum total cholesterol < 200mg/dl. 
 Around 54% of our patients had their serum cholesterol values 
<160mg%. 
 The mean total serum cholesterol level of this study group was 
168.09± 43.74 mg/dl. 
         Comparing with international studies,  
 MRFIT study48 showed clear association between low serum 
cholesterol levels especially below 160mg% with risk of ICH. 
 The mean cholesterol levels in ICH patients in MRFIT study was 
211.4 ± 43.9 mg/dl. 
101 
 
 The Honolulu Heart Program Yano et al92 showed increased risk of 
ICH in those with serum cholesterol <189 mg%. 
  In Konishi et al93 the mean serum total cholesterol in ICH patients 
was 164± 2mg%. 
Comparing with Indian studies, 
 In the Calicut study Ashraf  V. Valappil et al84  , 43% of ICH patients 
had serum cholesterol < 160mg%. 
 The mean serum total cholesterol in this study was 177 ± 39 mg%. 
TGL AND ICH 
 74% of patients in this study had their serum triglycerides level         
< 150 mg/dl. 
 The mean serum triglyceride among our study population was 
124.12± 50.76 mg/dl. 
 This is in concordance with Sturgeon et al94  where 81.48% of ICH 
patients had their serum triglyceride concentration <158mg%. 
 There is in discordance with Ashraf V. Valappil et al84 where mean 
triglyceride concentration in was 84 ± 35.5 mg%. 
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HDL-C AND ICH  
 76% of patients in our study had their serum HDL-C <40 mg/dl. 
 The mean HDL-Cholesterol level in the study population is       
32.45 ± 15.30 mg/dl. 
 The mean HDL-C in Ashraf V. Valappil et al84 was 42± 12mg% 
LDL-C AND ICH 
 In our study the serum LDL-cholesterol was <130mg /dl in 68 % of 
the ICH patients. 
 The mean LDL-Cholesterol level in our study population was 
108.26± 43.31mg/dl. 
 Comparing with Hiroyuki et al95 59.84% of ICH patients had LDL-C 
less than120mg% 
 In Calicut study Ashraf V. Valappil et al84  the mean LDL-C was  
         114± 37mg%. 
VLDL-C AND ICH 
 72% of ICH patients in our study had VLDL <30mg/dl. 
 The mean VLDL-Cholesterol in our study population was         
25.25± 10.14 mg/dl. 
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STRENGTHS AND LIMITATIONS OF THE STUDY 
 This study has included patients with intracerebral haemorrhage 
excluding the secondary causes of ICH. 
 Though many foreign studies and some Indian studies have been 
conducted in studying lipid profile in ICH, only few studies are 
available in south India especially Tamilnadu. Our study involves 
study of lipid profile in a group of 50 ICH patients in and around 
Thanjavur generating insights into the characteristics of the disease in 
Tamilnadu and its correlation with serum lipid levels. 
 The limitation of our study is that the dietary habits and physical 
activities of patients could not be explored.  
 This study is based on a single center and hospital based, hence the 
results obtained may not reveal the true burden of the disease in the 
community taken as a whole. 
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SUMMARY 
1. Majority of the patients of  intracerebral haemorrhage in our study 
were  > 55 years.  
2. Majority of the ICH patients in our study were males around 70%. 
3. Basal ganglia was the most common site of ICH. 
4.  Hypertension was the most significant risk factor in our study. This 
reinforces the fact that it is most important to control the elevated 
blood pressure in the community which has strong association with 
incidence of ICH. 
5. The total serum cholesterol concentration was low < 200mg/dl in      
72 % of our patients. 
6. The mean serum cholesterol was 168.09 ± 43.74 mg%. 
7. The serum triglycerides level was <150 mg/dl in 74% of patients in 
this study, with a mean of 124.12 ± 50.76 mg%. 
8. The HDL-C was < 40 mg/dl in 76% of patients in our study. 
9. The VLDL-C was < 30mg/dl in 72% of ICH patients in our study. 
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CONCLUSION 
 Majority of intracerebral haemorrhage patients in our study had lower 
levels of total cholesterol, triglyceride, high density lipoprotein, low 
density lipoprotein and very low density lipoprotein. 
 The following mechanism is proposed for inverse association of 
serum lipids and ICH. Cholesterol and triglycerides form an integral 
part of cell membrane of vascular endothelium and erythrocytes. 
When their levels are low, weakening of endothelium and increased 
erythrocyte fragility occurs, more significantly in the presence of 
hypertension which predispose to micro aneurysms and later on ICH.  
 Whether the inverse association of serum cholesterol and ICH is a 
true causal association or only by chance due to some other common 
confounding factor needs to be evaluated with large scale studies.  
 The public health impact of this inverse correlation of serum 
cholesterol and ICH has to be interpreted cautiously considering the 
baseline characteristics of the population. Aggressive methods of 
decreasing cholesterol levels to very low values should not be 
followed as a routine practice. Further studies with larger sample size 
concentrating on the pathophysiological effects of serum lipids and 
ICH are very much essential. 
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 CONSENT FORM 
 
I __________________________________________  hereby give consent 
to participate in the study conducted by DR DEEPIKA.S, Post graduate in 
the Department of  General Medicine ,Thanjavur Medical College & 
Hospital, Thanjavur – 613004 and to use my personal clinical data and 
result of investigation for the purpose of analysis and to study the nature of 
disease. I also give consent for further investigations 
 
 
Place : 
Date :       Signature of participant 
 
 
 
 
 
 
 STUDY OF LIPID PROFILE IN INTRACEREBRAL 
HAEMORRHAGE 
PROFORMA 
 NAME:                    D.O.A: 
 AGE:  SEX:        MALE/FEMALE                     D.O.D: 
          OCCUPATION:                                                            ADDRESS: 
 CHIEF COMPLAINTS: 
 HISTORY OF PRESENTING ILLNESS: 
            1. Weakness of limbs: 
                  Right upper limb:                  left upper limb: 
                  Right lower limb:                                         left lower limb: 
                  Duration:                                                      Onset: sudden / 
insidious 
          2. Loss of consciousness: YES/NO                   DURATION: 
          3. CONVULSIONS: 
a) DURATION: 
b) NO. OF EPISODES: 
c) TYPE OF CONVULSION: PARTIAL / GENERALISED 
  
4. OTHER ASSOCIATED COMPLAINTS: 
a. FEVER: 
b. HEADACHE: 
c. NAUSEA/ VOMITING: 
d. OTHERS: 
PAST HISTORY: 
• H/O  STROKE / INFECTIONS / TRAUMA  
• H/O  SHT / DM / TB /CKD/CAHD/BLEEDING DISORDER  
• H/O DRUG INTAKE 
FAMILY HISTORY: 
• ANY SIMILAR COMPLAINTS IN OTHER FAMILY 
MEMBERS 
• COMORBID ILLNESS:   YES / NO 
• FAMILY HISTORY OF OBESITY: 
PERSONAL HISTORY: 
• HABITS-  
o SMOKING:   YES/ NO.  IF YES, DURATION: 
o ALCOHOL:   YES/ NO.  IF YES, DURATION: 
 o TOBACCO CHEWING: YES/ NO 
o DRUG ABUSE:  YES/ NO.  IF YES, DRUG: 
o EXPOSURE TO STDs: YES/ NO 
• DIET:  
            EXAMINATION OF THE PATIENT 
GENERAL EXAMINATION: 
• BUILD AND NOURISHMENT: 
• PALLOR / ICTERUS/ CLUBBING / CYANOSIS/ PEDAL 
EDEMA / LYMPHADENOPATHY 
• MARKERS OF HYPERLIPIDEMIA: 
• ANY NEUROCUTANEOUS MARKERS:  
VITAL SIGNS: 
 PULSE:       RR: 
 BP:       TEMP: 
CENTRAL NERVOUS SYSTEM EXAMINATION: 
A) HIGHER MENTAL FUNCTIONS 
a. CONSCIOUSNESS: 
b. ORIENTATION TO : TIME/ PLACE / PERSON 
c. APPEARANCE AND BEHAVIOUR: 
 d. ATTENTION: 
e. VIGILANCE: 
f. LANGUAGE: 
g. MEMORY 
h. INTELLIGENCE 
B) CRANIAL NERVES    RT  
 LT 
1) SENSE OF SMELL 
2) ACUITY OF VISION 
FIELD OF VISION: 
COLOUR VISION: 
FUNDUS: 
      PTOSIS:      PRESENT / ABSENT 
      PUPILS- SIZE, SHAPE: REFLEXES: DIRECT / 
INDIRECT 
          3.4.6 .EXTRAOCULAR MOVEMENTS: 
5.    MOTOR: 
       SENSORY: 
  REFLEXES: CORNEAL / CONJUCTIVAL/JAW JERK 
 7.    MOTOR: 
  TASTE – ANT 2/3 rd TONGUE: 
 
8.   RINNE’S  
WEBER’S: 
9. TASTE –POST 1/3rd TONGUE, PALATE 
10. PALATAL MOVEMENT: 
GAG REFLEX: 
PHONATION: 
SWALLOWING: 
11 .STERNOCLEIDOMASTOID: 
 TRAPIZEUS: 
12. TONGUE MOVEMENTS: 
WASTING AND FASCICULATIONS: 
 
C) MOTOR SYSTEM:     RT  LT 
  NUTRITION 
   TONE 
  POWER 
   SHOULDER 
   ELBOW 
   WRIST 
   HAND GRIP 
   HIP 
KNEE 
   ANKLE 
  REFLEXES: 
  SUPERFICICAL - CORNEAL 
       CONJUNCTIVAL 
        PLANTAR 
  CREMASTRIC 
  ABDOMINAL 
     DEEP  -   JAW JERK  
  BICEPS 
                 TRICEPS 
                SUPINATOR 
       KNEE 
      ANKLE 
COORDINATION 
   UPPER LIMB- FINGER NOSE TEST 
          FINGER NOSE FINGER TEST 
   LOWER LIMB- HEEL KNEE TEST 
               TANDEM WALKING 
  ABNORMAL MOVEMENTS: 
D) SENSORY SYSTEM: 
   TOUCH 
   PAIN 
   TEMPERATURE 
   VIBRATION 
   JOINT POSITION SENSE 
   STEREOGNOSIS 
    TACTILE LOCALISATION 
   TWO POINT DISCRIMINATION 
   ROMBERG’S SIGN 
 E) CEREBELLAR SIGNS: 
  F) GAIT: 
G) SIGNS OF MENINGEAL IRRITATION: 
 H) SKULL AND SPINE: 
 OTHER SYSTEMS: 
 CARDIOVASCULAR SYSTEM: 
           RESPIRATORY SYSTEM: 
           PER ADBOMINAL EXAMINATION: 
           INVESTIGATIONS: 
1) URINE 
ALBUMIN 
SUGAR 
DEPOSITS 
2) BLOOD SUGAR: 
 3) BLOOD UREA:                               4) SERUM 
CREATININE: 
4) BT  :         CT:       
5) PT:   aPTT : 
6) SERUM ELECTROLYTES: 
a. SODIUM 
b. POTASSIUM 
 
7) LIPID PROFILE 
a. TOTAL CHOLESTEROL:                         
b.TRIGLYCERIDES 
c. LOW DENSITY LIPOPROTEIN:    
d.HIGH DENSITY LIPOPROTEIN 
e. VERY LOW DENSITY LIPOPROTEIN 
8) COMPLETE HAEMOGRAM 
a. Hb %:    e.   PLATELETS: 
b. TC:              f.   PCV: 
c. DC:    g.   ESR: 
d. RBC:    h.   PS  
9)      VCTC: 
 10) ECG:  
11) ECHO: 
12) CHEST XRAY: 
13) CT BRAIN: 
14) MRI BRAIN/MRA /MRV: 
15) CAROTID DOPPLER STUDY: 
16) USG ABDOMEN: 
17) OTHERS:  
 
 
 
  
  
  
  
  
 
 KEY TO MASTER CHART 
IP NO – IN PATIENT NUMBER 
M-MALE 
F-FEMALE 
L-LEFT 
R-RIGHT 
B/L- BILATERAL 
SHT-SYSTEMIC HYPERTENSION 
BP-BLOOD PRESSURE 
DM-DIABETES MELLITUS 
TOT-CHOL-TOTAL CHOLESTEROL IN MG/DL 
TGL-TRIGLYCERIDE IN MG/DL 
HDL-CHOL-HIGH DENSITY CHOLESTEROL IN MG/DL 
VLDL-CHOL-VERY LOW DENSITY CHOLESTEROL IN MG/DL 
LDL-CHOL-LOW DENSITY CHOLESTEROL IN MG/DL 
 
